Overview

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Stage III-IVB Head and Neck Cancer

Status:
Not yet recruiting

Trial end date:
2025-02-28

Target enrollment:

Participant gender:

Summary

This phase I/Ib trial tests the safety and best dose of ipatasertib in combination with the usual treatment approach chemotherapy given together with radiation therapy ("chemo-radiation") that can be safely and tolerably taken by patients with stage III-IVB head and neck cancer. AKT inhibitors such as, ipatasertib work to stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy to kill tumor cells and shrink tumors. Giving ipatasertib with chemoradiation may help cure head and neck cancer.

Phase:

Phase 1

Details

Lead Sponsor:

National Cancer Institute (NCI)

Treatments:

Cisplatin